FDA Approves Medtronic (MDT) Diabetes Management System
By Daniel James Hayden IV
March 17, 2010 8:17 AM
March 17, 2010 8:17 AM
Medtronic, Inc. (NYSE: MDT) announced on Wednesday that the company's MiniMed Paradigm REAL-Time Revel System diabetes management system was approved by the U.S. Food and Drug Administration.
The MiniMed Paradigm REAL-Time Revel System incorporates insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software into one system.
The system can issue alerts to warn users before a dangerous low or high glucose event takes place.
The insulin pump feature will give people greater control over insulin delivery, depending on their sensitivity to insulin.
(c) 2011 Benzinga.com. All rights reserved. This material may not be published in its entirety or redistributed without the approval of Benzinga.
We're Loving
